Published in Probl Tuberk Bolezn Legk on January 01, 2007
[New microbiological Techniques in diagnosis of tuberculosis]. Probl Tuberk (1996) 1.13
Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchips. Bull Exp Biol Med (2008) 1.11
Performance of Cepheid ® Xpert MTB/RIF ® and TB-Biochip ® MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis (2012) 0.93
Molecular typing of Mycobacterium tuberculosis circulated in Moscow, Russian Federation. Eur J Clin Microbiol Infect Dis (2010) 0.90
[Examining the ex vivo growth in the macrophages of Mycobacterium tuberculosis of various genotypic clusters]. Probl Tuberk Bolezn Legk (2006) 0.90
Serodiagnosis of tuberculosis: detection of mycobacterial antibodies and antigens. Tuber Lung Dis (1996) 0.87
[L-transformation of the mycobacterial population in the process of treating patients with newly detected destructive pulmonary tuberculosis]. Probl Tuberk (1980) 0.87
[Genotypic characteristics of Mycobacterium tuberculosis strains from the Republic of Tyva]. Probl Tuberk Bolezn Legk (2004) 0.84
[Molecular genotyping of Mycobacterium tuberculosis strains isolated from patients in the Samara region by the restriction DNA fragment length polymorphism]. Zh Mikrobiol Epidemiol Immunobiol (2004) 0.83
[Various approaches to tuberculosis diagnosis in patients with hemoblastosis]. Ter Arkh (2002) 0.82
Detection of rifampicin-resistant Mycobacterium tuberculosis strains by hybridization and polymerase chain reaction on a specialized TB-microchip. Bull Exp Biol Med (2001) 0.81
Association of various genetic markers with tuberculosis and other lung diseases in Tuvinian children. Tuber Lung Dis (1996) 0.81
[Molecular characteristics of multiresistant clinical strains of Mycobacterium tuberculosis isolated in Russia]. Mol Gen Mikrobiol Virusol (2000) 0.79
[Tuberculosis in patients with hemoblastoses]. Probl Tuberk (2002) 0.78
[Interaction of Mycobacteria isolated from sarcoidosis patients with antituberculosis antibodies]. Probl Tuberk (1997) 0.77
[Clinical picture of tuberculosis with concomitant hemoblastoses]. Ter Arkh (2004) 0.77
[Impact of M. tuberculosis genotype on survival in mice with experimental tuberculosis]. Probl Tuberk Bolezn Legk (2007) 0.77
[Clinical aspects of pulmonary tuberculosis in patients with borderline disorders of carbohydrate metabolism]. Probl Tuberk (1993) 0.77
[Preponderance of Mycobacterium tuberculosis strains of the family Beijing and risk factors of their transmission in the Samara Region]. Probl Tuberk Bolezn Legk (2006) 0.77
[Biological properties of M. Tuberculosis W cluster strains]. Probl Tuberk Bolezn Legk (2008) 0.76
[Mycobacterium tuberculosis strain transmission caused by migratory processes in the Russian Federation (in case of populational migration from the Caucasian Region to Moscow and the Moscow Region)]. Probl Tuberk Bolezn Legk (2006) 0.76
[Specific features of cellular immunity of pulmonary tuberculosis in patients with diabetes mellitus]. Probl Tuberk (1997) 0.76
[Changes in carbohydrate metabolism in patients with tuberculosis]. Vestn Ross Akad Med Nauk (1995) 0.75
New 5-modified pyrimidine nucleoside inhibitors of mycobacterial growth. Acta Naturae (2010) 0.75
[The isolation and characteristics of monoclonal antibodies to Mycobacterium smegmatis and M. kansasii]. Probl Tuberk (1996) 0.75
[Genotyping mycobacteria, isolated from incarcerated tuberculosis patients]. Probl Tuberk (2001) 0.75
[Dynamics of L-form Mycobacteria excretion in the treatment of patients with newly diagnosed destructive pulmonary tuberculosis]. Probl Tuberk (1978) 0.75
[Examining of humoral immunity on mycobacteria antigens in sarcoidosis]. Probl Tuberk (1997) 0.75
[Identification of mycobacteria in sputum by determining antigens in the culture medium]. Probl Tuberk (1994) 0.75
[Comparative characterization of the antigenic composition of M. leprae and M. lufu]. Probl Tuberk (2001) 0.75
Effect of exogenous cardiolipin on the growth and viability of Mycobacterium tuberculosis H37Rv in vitro. Dokl Biol Sci (2010) 0.75
[Experience with fenazid in perperas with respiratory tuberculosis and post-tuberculous changes in the lung]. Probl Tuberk Bolezn Legk (2004) 0.75
[Antimycobacterial activity of a dry birch bark extract on a model of experimental pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2006) 0.75
[Preparation and characteristics of murine monoclonal antibodies to the Salmonella typhimurium K-antigen]. Biull Eksp Biol Med (1994) 0.75
[Level and spectrum of tuberculosis antibodies in mice sensitive and resistant to tuberculosis]. Probl Tuberk (1993) 0.75
[Humoral immune response in humans and animals infected and immunized with Mycobacteria of the MAIS complex]. Probl Tuberk (1994) 0.75
[The comparative cultural-biochemical and immunochemical identification of laboratory strains of cultured mycobacteria from leprous patient lesions and from soil]. Probl Tuberk (2000) 0.75
Effects of liposomes of different lipid composition on in vitro growth of Mycobacterium tuberculosis H37Rv. Bull Exp Biol Med (2009) 0.75
[Role of age factors in the clinical picture of pulmonary tuberculosis]. Sov Med (1970) 0.75
[Length of stay in the tuberculosis hospital of persons with focal forms of pulmonary tuberculosis]. Probl Tuberk (1974) 0.75
[Comparative effectiveness of different methods for the microbiological study of resected pulmonary tuberculomas]. Zh Mikrobiol Epidemiol Immunobiol (1987) 0.75
[Effect of rifampicin on the L transformation of a mycobacterial population in patients with destructive pulmonary tuberculosis]. Probl Tuberk (1986) 0.75
[L-forms of Mycobacterium tuberculosis during chemotherapy of patients with chronic destructive pulmonary tuberculosis]. Probl Tuberk (1983) 0.75
[Isolation of mycobacteria L forms as a prognostic criterion of recurrence and aggravation of tuberculosis in patients with extended residual tuberculous lesions of the lungs]. Probl Tuberk (1989) 0.75
[Clinical picture and course of chronic destructive pulmonary tuberculosis in patients secreting L forms of the causative agent]. Probl Tuberk (1985) 0.75
[Clinico-bacteriological characteristics of tuberculosis of peripheral lymph nodes]. Probl Tuberk (1984) 0.75
[Characterization of an experimental model of endogenously reactivated tuberculosis: detection of Mycobacterial DNA during chemotherapy]. Probl Tuberk (2002) 0.75
[Results of controlled clinical trials of intensive isoniazid therapy]. Probl Tuberk (1980) 0.75
[Characteristics of clinical features of tuberculosis of the peripheral lymph nodes with the isolation of L forms of Mycobacterium tuberculosis]. Probl Tuberk (1983) 0.75
[The identification of the antigenic determinants of Mycobacterium leprae passed through laboratory animals by using monoclonal antibodies]. Zh Mikrobiol Epidemiol Immunobiol (1994) 0.75
[Change in the function of the kidneys and the elimination of antitubercular preparations with their side effects in patients with pulmonary tuberculosis]. Probl Tuberk (1975) 0.75
[Comparative evaluation of several functional tests of the liver in patients with pulmonary tuberculosis with side-reactions to tuberculostatic preparations]. Ter Arkh (1969) 0.75
[S and R forms of Mycobacterium tuberculosis as a problem of producing cloned and phenotypically competent strains]. Probl Tuberk (1996) 0.75
[Passage of fibrinogen and blood serum proteins through tissue barriers in patients with pulmonary tuberculosis]. Probl Tuberk (1970) 0.75
[Principles and methods of immunodiagnosis in tuberculosis]. Vestn Ross Akad Med Nauk (1995) 0.75
[A role of the biological chip test in the determination of rifampicin resistance in Mycobacteria in adolescents with active pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2004) 0.75
[Clinical characteristics of newly detected destructive pulmonary tuberculosis in patients excreting mycobacterial L forms]. Probl Tuberk (1980) 0.75
[Chemotherapy of tuberculosis: problems and perspectives]. Vestn Ross Akad Med Nauk (2012) 0.75
[Regulatory effect of complex of natural cytokines and antimicrobial peptides on murine macrophages infected with multidrug-resistant Mycobacterium tuberculosis]. Zh Mikrobiol Epidemiol Immunobiol (2010) 0.75
[Effect of tuberculin and insulin on tissue permeability in patients with pulmonary tuberculosis]. Probl Tuberk (1967) 0.75
[Increasing the effectiveness of microbiological diagnosis of limited nondestructive pulmonary tuberculosis]. Probl Tuberk (1989) 0.75
[Detection of mutations in codon 306 of the embB gene for molecular genetic characterization of clinical Mycobacterium tuberculosis strains]. Probl Tuberk Bolezn Legk (2009) 0.75
[The practical use of monoclonal antibodies to Mycobacterium tuberculosis]. Zh Mikrobiol Epidemiol Immunobiol (1994) 0.75
[Detection of Mycobacterial antigens in tuberculous pleuritis, empyema and meningitis]. Probl Tuberk (1995) 0.75
[Levamisole in the treatment of late middle-aged pulmonary tuberculosis patients]. Probl Tuberk (1987) 0.75
[Study of characteristics of the antigen structure of different mycobacteria (epitope mapping) with monoclonal antibodies]. Biull Eksp Biol Med (1998) 0.75
[Advances in microbiological diagnosis of tuberculosis and sarcoidosis]. Probl Tuberk (1996) 0.75
[On the effect of insulin on the penetration of blood serum proteins through the inflammation-modified tissue barrier in tuberculosis patients]. Probl Endokrinol Gormonoter (1969) 0.75
[Symposium "Immunodiagnosis and pathogenesis of Mycobacterial diseases"]. Probl Tuberk (1994) 0.75
[Dynamics of the indicators of blast transformation reaction in complex chemo- and tuberculin therapy of tuberculosis]. Probl Tuberk (1975) 0.75
[Biological characteristics of M. tuberculosis and difficulties in microbiological diagnosis of tuberculosis]. Probl Tuberk (1995) 0.75
[Biological properties of M. leprae passaged in laboratory animals]. Probl Tuberk (1995) 0.75
[The use of allele-specific amplification and analysis of conformational polymorphism for detection of rifampicin resistance in clinical isolates of Mycobacterium tuberculosis]. Biull Eksp Biol Med (1999) 0.75
[Characteristics of abacillary tuberculosis in school-age children and adolescents and laboratory methods of its diagnosis]. Probl Tuberk Bolezn Legk (2004) 0.75
[The level of cytokines in the ex vivo infection of murine macrophages with Mycobacterium tuberculosis complex]. Probl Tuberk Bolezn Legk (2009) 0.75
[Role of PCR analysis in complex bacteriological studies in phthisiology]. Probl Tuberk (2001) 0.75
[On the effect of cortisone on the penetration by blood serum proteins of the inflammation-modified tissue barrier in tuberculosis]. Probl Endokrinol Gormonoter (1969) 0.75
[Microbiological diagnosis of tuberculosis]. Vestn Ross Akad Med Nauk (1995) 0.75
[Use of a mini-sequencing test, followed by the MALDI-TOF mass-spectrometric analysis to evaluate rifampicin and izoniazid resistance in Mycobacterium tuberculosis circulating in the Russian Federation]. Probl Tuberk Bolezn Legk (2007) 0.75
[L forms of Mycobacterium tuberculosis in chronic pleural empyema in tuberculosis patients]. Probl Tuberk (1981) 0.75
[Sarcoidous pneumonia]. Probl Tuberk (1985) 0.75
[Effect of hormonal therapy of prednisolone and insulin on the dynamics of penetration of streptomycin through the barrier of inflammed tissue in pulmonary tuberculosis]. Antibiotiki (1970) 0.75
[Improving of methods of production and screening of monoclonal antibodies to Salmonella antigens]. Klin Lab Diagn (1995) 0.75
[Comparative characterization of molecular and microbiological methods for controlling chemotherapy in new cases of pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2004) 0.75
[Formation of aspergilloma in a patient with pulmonary tuberculosis]. Probl Tuberk (1969) 0.75
[Microbiological research on fluid obtained during bronchoalveolar lavage of patients with circumscribed pulmonary tuberculosis]. Probl Tuberk (1988) 0.75
[Clinico-radiographic peculiarities of nonspecific pneumonia developing against a background of posttuberculous changes]. Probl Tuberk (1976) 0.75
[Specific antisera to mycobacteria]. Zh Mikrobiol Epidemiol Immunobiol (1994) 0.75
[Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)]. Probl Tuberk Bolezn Legk (2004) 0.75
[Diagnosis of latent primary intrathoracic tuberculosis of respiratory system in the phase of calcification in children]. Probl Tuberk Bolezn Legk (2004) 0.75
[Efficiency of chemotherapy of destructive pulmonary tuberculosis, based on the results of rapid detection of drug sensitivity to isoniazid and rifampicin with the "TB-Biochip" test system]. Probl Tuberk Bolezn Legk (2006) 0.75
[Pulmonary tuberculosis and diabetes mellitus]. Probl Tuberk (1990) 0.75
[On the state of the blood-tissue barriers in tuberculosis and its antibacterial therapy]. Ter Arkh (1967) 0.75
[Detection and characteristics of rpoB gene mutations in rifampicin-resistant clinical strains of M. tuberculosis]. Probl Tuberk (1999) 0.75
[Clinical value of microchip technology in determination of drug resistance of Mycobacterium tuberculosis]. Probl Tuberk (2002) 0.75
[Inhibiting effect of complex of natural cytokines and cationic antimicrobial peptides on the growth of Mycobacterium tuberculosis H37Rv in vitro]. Zh Mikrobiol Epidemiol Immunobiol (2009) 0.75
[Penetration of antitubercular drugs through the tissue barriers and their side-effects in tuberculous patients]. Probl Tuberk (1972) 0.75
[Characteristics of a Mycobacterium population growing in pulmonary tuberculomas]. Probl Tuberk (1987) 0.75
[Affinity isolation of mycobacterial antigens on monoclonal antibodies]. Probl Tuberk (1995) 0.75
[Synthesis and biological properties of α-thymidine 5'-aryl phosphonates]. Bioorg Khim (2015) 0.75